Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Wong, Sandy W.
Chaulagain, Chakra P.
Klein, Andreas K.
Miller, Kenneth B.
Comenzo, Raymond L.
Funding for this research was provided by:
Multiple Myeloma Research Foundation
Text and Data Mining valid from 2018-10-16
10 August 2018
6 October 2018
16 October 2018